These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 23406827)

  • 21. Immunological responses following administration of a genotype 1a/1b/2/3a quadrivalent HCV VLP vaccine.
    Christiansen D; Earnest-Silveira L; Chua B; Meuleman P; Boo I; Grubor-Bauk B; Jackson DC; Keck ZY; Foung SKH; Drummer HE; Gowans EJ; Torresi J
    Sci Rep; 2018 Apr; 8(1):6483. PubMed ID: 29691437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequency, Private Specificity, and Cross-Reactivity of Preexisting Hepatitis C Virus (HCV)-Specific CD8+ T Cells in HCV-Seronegative Individuals: Implications for Vaccine Responses.
    Zhang S; Bakshi RK; Suneetha PV; Fytili P; Antunes DA; Vieira GF; Jacobs R; Klade CS; Manns MP; Kraft AR; Wedemeyer H; Schlaphoff V; Cornberg M
    J Virol; 2015 Aug; 89(16):8304-17. PubMed ID: 26041301
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances in hepatitis C virus vaccines, part two: advances in hepatitis C virus vaccine formulations and modalities.
    Roohvand F; Kossari N
    Expert Opin Ther Pat; 2012 Apr; 22(4):391-415. PubMed ID: 22455502
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Broadening CD4
    Filskov J; Mikkelsen M; Hansen PR; Christensen JP; Thomsen AR; Andersen P; Bukh J; Agger EM
    J Virol; 2017 Jul; 91(14):. PubMed ID: 28446674
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chimeric hepatitis B virus (HBV)/hepatitis C virus (HCV) subviral envelope particles induce efficient anti-HCV antibody production in animals pre-immunized with HBV vaccine.
    Beaumont E; Roingeard P
    Vaccine; 2015 Feb; 33(8):973-6. PubMed ID: 25596457
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dendritic cell-based immunity and vaccination against hepatitis C virus infection.
    Zhou Y; Zhang Y; Yao Z; Moorman JP; Jia Z
    Immunology; 2012 Aug; 136(4):385-96. PubMed ID: 22486354
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enveloped virus-like particle platforms: vaccines of the future?
    Pitoiset F; Vazquez T; Bellier B
    Expert Rev Vaccines; 2015 Jul; 14(7):913-5. PubMed ID: 25968245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An overview of hepatitis C vaccines.
    Garcia A; Fernandez S; Toro F; De Sanctis JB
    Recent Pat Inflamm Allergy Drug Discov; 2014; 8(2):85-91. PubMed ID: 25000932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis B virus core particles containing multiple epitopes confer protection against enterovirus 71 and coxsackievirus A16 infection in mice.
    Huo C; Yang J; Lei L; Qiao L; Xin J; Pan Z
    Vaccine; 2017 Dec; 35(52):7322-7330. PubMed ID: 29129453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Designing an HCV vaccine: a unique convergence of prevention and therapy?
    Walker CM
    Curr Opin Virol; 2017 Apr; 23():113-119. PubMed ID: 28550816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of route of delivery on heterologous protection against HCV induced by an adenovirus vector carrying HCV structural genes.
    Guan J; Wen B; Deng Y; Zhang K; Chen H; Wu X; Ruan L; Tan W
    Virol J; 2011 Nov; 8():506. PubMed ID: 22054309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of a hepatitis C virus-like particle vaccine produced in a human hepatocyte-derived cell line.
    Earnest-Silveira L; Chua B; Chin R; Christiansen D; Johnson D; Herrmann S; Ralph SA; Vercauteren K; Mesalam A; Meuleman P; Das S; Boo I; Drummer H; Bock CT; Gowans EJ; Jackson DC; Torresi J
    J Gen Virol; 2016 Aug; 97(8):1865-1876. PubMed ID: 27147296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospects for a hepatitis C virus vaccine.
    Hsu HH; Abrignani S; Houghton M
    Clin Liver Dis; 1999 Nov; 3(4):901-15. PubMed ID: 11291258
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in DNA immunization against hepatitis C virus infection.
    Alvarez-Lajonchere L; Dueñas-Carrera S
    Hum Vaccin; 2009 Aug; 5(8):568-71. PubMed ID: 19736511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Challenges for development of hepatitis C virus vaccines.
    Prince AM
    FEMS Microbiol Rev; 1994 Jul; 14(3):273-7. PubMed ID: 8086198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Toward DNA-Based T-Cell Mediated Vaccines to Target HIV-1 and Hepatitis C Virus: Approaches to Elicit Localized Immunity for Protection.
    Mekonnen ZA; Grubor-Bauk B; Masavuli MG; Shrestha AC; Ranasinghe C; Bull RA; Lloyd AR; Gowans EJ; Wijesundara DK
    Front Cell Infect Microbiol; 2019; 9():91. PubMed ID: 31001491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatitis C vaccine: supply and demand.
    Strickland GT; El-Kamary SS; Klenerman P; Nicosia A
    Lancet Infect Dis; 2008 Jun; 8(6):379-86. PubMed ID: 18501853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment and vaccination for hepatitis C: present and future.
    Jawaid A; Khuwaja AK
    J Ayub Med Coll Abbottabad; 2008; 20(1):129-33. PubMed ID: 19024206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Virus-like particles produced in plants as potential vaccines.
    Scotti N; Rybicki EP
    Expert Rev Vaccines; 2013 Feb; 12(2):211-24. PubMed ID: 23414411
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses.
    Houghton M
    Immunol Rev; 2011 Jan; 239(1):99-108. PubMed ID: 21198667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.